22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Creative destruction tells us that eventually the new replaces the old. However, sometimes the imper...
Read More >
The increasing and dynamic impact of the novel Coronavirus (COVID-19) is tangible. For example, on J...
Read More >
A tough situation. Could it have been handled better? The Pennsylvania Department of Insurance will...
Read More >
Since #MeToo brought non-disclosure agreements (NDAs) into the spotlight, there has been a flurry of...
Read More >
People involved in mergers and acquisitions know there are risks inherent in every deal, including t...
Read More >
In recent months, European states have raced to implement protections against opportunistic acquisit...
Read More >